PharVision Advisers’s Privia Health PRVA Stock Holding History

PharVision Advisers’s Portfolio PRVA Stock Details PRVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,231	Closed	-$259K	–	472
2024 Q4	$259K	Buy	+13,231	New	+$262K	0.22%	206

Other funds holding PRVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's PRVA Position: Q1 2025 in Review

PharVision Advisers sold out of Privia Health (PRVA) in Q1 2025, closing a stake of 13,231 shares — an estimated $259K sold.

PharVision Advisers first reported a position in PRVA in Q4 2024 and held it in 1 quarter. The position peaked at $259K in Q4 2024. 248 funds tracked by Wall St. Rank hold PRVA as of Q1 2025.

PharVision Advisers reported no remaining Privia Health position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 13,231 Privia Health shares in Q1 2025, an estimated $259K.
PharVision Advisers first reported a position in Privia Health in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Privia Health position peaked at $259K in Q4 2024.
248 funds tracked by Wall St. Rank held Privia Health as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.